Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of JW0107 vs JW0106 + C2101 in Healthy Volunteers
NCT06816719Phase 1Completed
- Sponsor
- JW Pharmaceutical Corporation
- Start
- Sep 2024
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of JW-0107 in dyslipidemia and hypertension (HTN) (2 arms), sponsored by JW Pharmaceutical Corporation. Primary endpoints: Area Under the Concentration-time Curve from time zero to the last measurable concentration at Day 4 and Maximum Plasma Concentration at Day 4. Started Sep 2024; status: completed.
02
Drugs
JW-0107
03
Conditions
dyslipidemiahypertension (HTN)
Beyond the preview
Go deeper on NCT06816719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06816719.